Aptevo Research

Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company utilizes its proprietary ADAPTIR and CHELATE platforms to design next-generation antibodies that can enhance the immune system's ability to target and destroy tumor cells. Its lead clinical candidate, APVO436, is being evaluated for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Aptevo's pipeline also includes ALG.APV-527, a bispecific candidate targeting 4-1BB and 5T4, developed in collaboration with Alligator Bioscience. The company was spun off from Emergent BioSolutions in 2016 and is headquartered in Seattle, Washington.